Showing results (121-130 of 132) with videos related to
Sort By:
Pageof 14
Cell Reports. Medicine|November 17, 2022
Re-purposing the pro-senescence properties of doxorubicin to introduce immunotherapy in breast cancer brain metastasisRebeca Uceda-Castro, Andreia S Margarido, Lesley Cornet, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 2018
MELK Inhibition in Diffuse Intrinsic Pontine GliomaMichaël H Meel, Mark C de Gooijer, Miriam Guillén Navarro, et al.Cancer Research|December 29, 2025
C-terminal Truncation and Fusion Partner Determine Oncogenicity of FGFR3Julia Yemelyanenko, Jinhyuk Bhin, Eline van der Burg, et al.Cell Reports. Medicine|March 20, 2024
Targeting of vulnerabilities of drug-tolerant persisters identified through functional genetics delays tumor relapseMengnuo Chen, Sara Mainardi, Cor Lieftink, et al.Immunity|January 4, 2025
Adoptive T cell therapy targeting an inducible and broadly shared product of aberrant mRNA translationJulien Champagne, Morten M Nielsen, Xiaodong Feng, et al.Nature|March 10, 2022
Tryptophan depletion results in tryptophan-to-phenylalanine substitutantsAbhijeet Pataskar, Julien Champagne, Remco Nagel, et al.Cell Reports. Medicine|November 17, 2022
Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancerKatrin J Frank, Antonio Mulero-Sánchez, Alexandra Berninger, et al.Journal of the National Cancer Institute|August 14, 2013
Effects of the selective MPS1 inhibitor MPS1-IN-3 on glioblastoma sensitivity to antimitotic drugsBakhos A Tannous, Mariam Kerami, Petra M Van der Stoop, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 14, 2020
Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine GliomaMichaël H Meel, Mark C de Gooijer, Dennis S Metselaar, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2019
EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based ChemotherapyJulian Puppe, Mark Opdam, Philip C Schouten, et al.Pageof 14